IVL Platform Competition Splits Into Three Mechanisms

Stryker announced on May 7 that it had closed its acquisition of Amplitude Vascular Systems, adding the Pulse intravascular lithotripsy platform to a peripheral vascular portfolio that already includes the Inari Medical clot-removal business acquired last year. On May 11, a first-in-human report on the Boston Scientific Seismiq 4CE Coronary IVL Catheter was published in Circulation: Cardiovascular Interventions, with the RESTORE study showing feasibility and high procedural success in 41 patients with severely calcified coronary lesions. The same day, Johnson & Johnson disclosed 30-day follow-up data from a 30-patient prospective multicenter study of its Ottava robotic platform in gastric bypass, with all procedures completed robotically and no device-related adverse events, in a package now supporting the company’s FDA de novo submission. Read together, the three disclosures describe an interventional platform market that is rebuilding around three distinct technical mechanisms in calcium modification and a strategic-acquirer environment that is paying premiums for cleared platforms whose evidence base reads through the route the platform was designed to anchor.

Stryker Closes Amplitude and Adds CO2 Pressure-Wave Lithotripsy

Stryker announced on May 7 that it had completed the acquisition of Amplitude Vascular Systems, the Boston-based developer of the Pulse intravascular lithotripsy platform, per MedTech Dive. Financial terms were not disclosed, and the transaction closed less than a month after the definitive agreement was announced. Amplitude was running a U.S. pivotal study at the time of the deal and had raised $36 million in January 2025 to fund the device launch and trial program. The Pulse platform generates pressure waves through carbon dioxide delivered via a balloon catheter to fracture severely calcified arterial calcium and restore vessel patency, and the system has been designed for both peripheral and coronary applications. Stryker chief executive Kevin Lobo positioned the acquisition as a continuation of an active mergers and acquisitions cadence the company expects to maintain through the rest of 2026 and into 2027, with the Pulse platform anchoring the peripheral vascular portfolio alongside the Inari Medical clot-removal business Stryker acquired in 2025 for approximately $4.9 billion.

The structural read for surgical robotics and advanced interventional founders is that calcium modification has now become a portfolio category large strategic acquirers are building around as a multi-platform stack rather than as a single-product line. Shockwave Medical, the original sonic IVL pioneer, was acquired by Johnson & Johnson in 2024 for $13.1 billion and now anchors the J&J Medtech peripheral and coronary vascular portfolio. Stryker has now built a competing peripheral vascular stack on Inari clot removal plus Amplitude Pulse IVL, and the company has signaled a continued acquisition cadence in the same calcium and clot category. The platforms whose calcium modification or vascular intervention technology fits inside the portfolio architecture of one of the major strategic acquirers gain a credible path to scale through the acquirer’s commercial channel. The platforms whose technology overlaps with the acquirer’s existing position face a steeper distribution build and a more cautious strategic-conversation profile when the platform reaches commercial readiness.

Boston Scientific RESTORE First-in-Human and the Coronary IVL Path

Boston Scientific reported first-in-human results for its Seismiq 4CE Coronary IVL Catheter on May 11, with the RESTORE study published in Circulation: Cardiovascular Interventions. The single-arm study enrolled 41 patients with a mean age of 71.7 years who presented with stable, unstable, or silent ischemia and were scheduled for percutaneous coronary intervention on severely calcified coronary lesions. The report showed that the Seismiq 4CE catheter delivered substantial improvement in luminal area, high rates of clinical procedural success, and excellent post-procedural stent expansion. The Seismiq platform uses laser energy to generate acoustic pressure waves that fracture calcium deposits, a mechanism distinct from the sonic-based Shockwave platform and the CO2-based Amplitude Pulse platform Stryker now owns. The Seismiq IVL system currently holds FDA approval for the treatment of peripheral artery disease and remains investigational in coronary indications, with the RESTORE first-in-human report positioning the coronary catheter for the next phase of the U.S. regulatory program.

The structural read for surgical robotics and advanced interventional founders is that the coronary calcium modification market is now a three-way contest among technical mechanisms that were single-mechanism categories twelve months ago. The clinical performance data the RESTORE report produced is the kind of clean first-in-human evidence base the regulatory pathway and the strategic-acquirer evaluation both price at the premium end of the coronary intervention category, and the laser-acoustic mechanism gives Boston Scientific a differentiated technical position against the sonic and CO2 mechanisms the J&J and Stryker stacks anchor. Founders building advanced interventional platforms in the vascular space now have to position the platform within a coronary and peripheral category where three large strategic acquirers each anchor a distinct technical mechanism, where the strategic-acquirer evaluation prices the platform on the mechanism fit with the acquirer’s stack rather than on a generic IVL capability, and where the clinical-evidence base has to read against the specific mechanism category the platform will compete inside.

J&J Ottava Gastric Bypass Study and the De Novo Submission Profile

Johnson & Johnson reported on May 11 that a 30-patient prospective multicenter study of its Ottava soft-tissue surgical robotic platform in laparoscopic Roux-en-Y gastric bypass met its safety and efficacy endpoints through 30 days post-surgery, per MedTech Dive. Average weight loss across the 30-day window was approximately 30 pounds, and all procedures were completed robotically without conversion to a non-robotic surgical approach. No adverse events related to the Ottava device were reported. The 30-day follow-up data package is now part of the de novo authorization submission J&J filed with the FDA in January, with the submission targeting a general-surgery indication that covers Roux-en-Y gastric bypass, gastric sleeve, small bowel resection, and hiatal hernia repair, alongside an investigational device exemption trial in inguinal hernia repair that is running in parallel. J&J Medtech chief scientific officer Peter Schulam described the architecture as one designed to integrate into existing infrastructure and remove practical barriers to broader adoption. The company expects an Ottava U.S. launch by the end of 2026, pending FDA authorization.

The structural read for surgical robotics founders is that J&J has now produced the second consecutive Ottava pivotal-quality readout in a major bariatric or upper-abdominal indication on a study architecture engineered against the de novo submission profile, and the platform is on a credible path to its first U.S. clearance by the end of the calendar year. For founders building multi-specialty soft-tissue surgical robotic platforms, the Ottava trajectory now describes the integrated-evidence profile the strategic-acquirer evaluation prices when the cleared platform reaches commercial submission readiness. For founders building specialist soft-tissue platforms, the trajectory now reframes the timeline pressure on the specialist platform whose first cleared indication is being read against a multi-specialty platform that has already produced two clean pivotal-quality readouts in bariatric procedures. The specialist platform that arrives at its first commercial customer in the second half of 2026 will be evaluated against an Ottava that hospital programs are at the same moment evaluating, and the procurement evaluation will read the specialist platform against the integrated J&J stack rather than against the standalone specialist platform alone.

What the Three Disclosures Mean for the Founder Operating Plan

Read across the IVL platform closes, the coronary first-in-human report, and the Ottava gastric bypass readout, the structural lesson for surgical robotics and advanced interventional founders is consistent across the three segments. The strategic-acquirer environment is paying premiums for cleared platforms whose evidence base reads against the specific route the platform was designed to anchor and whose technical mechanism fits inside the portfolio architecture the acquirer is building around the category. The clean first-in-human disclosure, the de novo submission package designed against the agency’s preferred clearance pathway, and the technical-mechanism positioning that matches the acquirer’s portfolio stack are now the three operating-plan lines that compound through the build years into the integrated-evidence and integrated-stack multiple the strategic conversation actually prices.

For surgical robotics and advanced interventional founders running specialist platforms through 2026, the operating plan question is which architectural and partnership decisions need to be made now to produce the integrated-evidence and integrated-stack profile in three years. The Stryker-Amplitude close describes how the strategic-acquirer portfolio architecture extends into the next adjacent category once a foundational platform position is in place. The Boston Scientific RESTORE first-in-human report describes what the clinical-evidence base looks like when the study architecture is designed against the route the agency and the strategic acquirer both read. The J&J Ottava gastric bypass readout describes what the de novo submission profile looks like when the pivotal-quality readout architecture is engineered against the indication the agency is going to support. Founders building specialist surgical robotics or interventional platforms have to run the architectural, partnership, and evidence-design work as Day-1 strategy lines rather than as late-cycle deliverables, and the platforms whose work compounds through the build years arrive at the strategic conversation with the integrated profile the multiple actually prices.